

## STILNOX 10mg tablets Prescribing Information

### WARNING: COMPLEX SLEEP BEHAVIORS

Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following use of Stilnox. Some of these events may result in serious injuries, including death. Discontinue Stilnox immediately if a patient experiences a complex sleep behavior [see *Contraindications (4) and Warnings and Precautions (8.1)*].

#### 1 NAME OF THE MEDICINAL PRODUCT

STILNOX 10mg Tablets

#### 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains zolpidem tartrate 10 mg

Excipients with known effect:

Each Stilnox tablet contains 90.4 mg lactose monohydrate

#### 3 PHARMACEUTICAL FORM

Stilnox tablets are white to off-white film coated oblong tablets

#### 4 THERAPUTIC INDICATIONS AND USAGE

Indications are limited to treatment of severe sleep disorders in the following cases:

- Occasional insomnia
- Transient insomnia.

The short-term treatment of insomnia in situations where the insomnia is debilitating or is causing severe distress to the patient. As with all hypnotics long term use is not recommended and a course of treatment should not exceed 4 weeks.

Hypnotics should generally be limited to 7 to 10 days of use, and reevaluation of the patient is recommended if they are to be taken for more than 2 to 3 weeks.

#### 5 DOSAGE AND ADMINISTRATION

##### 5.1 Dosage in Adults

Use the lowest effective dose for the patient. The recommended initial dose is 5 mg for women and either 5 or 10 mg for men, taken only once per night immediately before bedtime with at least 7-8 hours remaining before the planned time of awakening. If the 5 mg dose is

not effective, the dose can be increased to 10 mg. In some patients, the higher morning blood levels following use of the 10 mg dose increase the risk of next day impairment of driving and other activities that require full alertness [see Warnings and Precautions (8.2)]. The total dose of Stilnox should not exceed 10 mg once daily immediately before bedtime. Stilnox should be taken as a single dose and should not be readministered during the same night.

The recommended initial doses for women and men are different because zolpidem clearance is lower in women.

## **5.2 Special Populations**

Elderly or debilitated patients may be especially sensitive to the effects of zolpidem tartrate. Patients with hepatic insufficiency do not clear the drug as rapidly as normal subjects. The recommended dose of Stilnox in both of these patient populations is 5 mg (half tablet) once daily immediately before bedtime [see *Warnings and Precautions (8. 2); Use in Specific Populations (11.4)*].

Stilnox should not be used in patient with severe hepatic insufficiency [see *Contraindications (7)*].

## **5.3 Use with CNS Depressants**

Dosage adjustments may be necessary when Stilnox is combined with other CNS depressant drugs because of the potentially additive effects [see *Warnings and Precautions (8.1, 8.7)*].

## **5.4 Administration**

The effect of Stilnox may be slowed by ingestion with or immediately after a meal.

## **6 DOSAGE FORMS AND STRENGTHS**

Stilnox is available in 10 mg strength tablets for oral administration.

It is possible to take half of tablet (5mg) if needed [see *Special population (2.2)*]

## **7 CONTRAINDICATIONS**

Stilnox is contraindicated in patients:

- who have experienced complex sleep behaviors after taking Stilnox [see *Warnings and Precautions (8.1)*].
- with known hypersensitivity to zolpidem or to any of the inactive ingredients in the formulation listed in *Description (see section 14)*. Observed reactions include anaphylaxis and angioedema [see *Warnings and Precautions (8. 4)*].
- severe hepatic insufficiency[see *Dosage and Administration (2.2);Warnings and Precautions (5. 7)*].

## **8 WARNINGS AND PRECAUTIONS**

As with all hypnotics, long term use of zolpidem is not recommended. Treatment should be as short as possible and should not exceed 4 weeks, including the tapering-off period.

## 8.1 Complex Sleep Behaviors

Complex sleep behaviors, including sleep-walking, sleep-driving, and engaging in other activities while not fully awake, may occur following the first or any subsequent use of Stilnox. Patients can be seriously injured or injure others during complex sleep behaviors. Such injuries may result in a fatal outcome. Other complex sleep behaviors (e.g., preparing and eating food, making phone calls, or having sex) have also been reported. Patients usually do not remember these events. Postmarketing reports have shown that complex sleep behaviors may occur with Stilnox alone at recommended doses, with or without the concomitant use of alcohol or other central nervous system (CNS) depressants [see *Drug Interactions (7.1)*]. Discontinue Stilnox immediately if a patient experiences a complex sleep behavior [see *Contraindications (7)*]

## 8.2 CNS Depressant Effects and Next-Day Impairment

Stilnox, like other sedative-hypnotic drugs, has CNS depressant effects. Coadministration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression [see *Drug Interactions (10.1)*]. Dosage adjustments of Stilnox and of other concomitant CNS depressants may be necessary when Stilnox is administered with such agents because of the potentially additive effects. The use of Stilnox with other sedative-hypnotics (including other zolpidem products) at bedtime or the middle of the night is not recommended [see *Dosage and Administration (5.3)*].

The risk of next-day psychomotor impairment, including impaired driving, is increased if Stilnox is taken with less than a full night of sleep remaining (7- to 8 hours); if a higher than the recommended dose is taken; if coadministered with other CNS depressants or alcohol; or if coadministered with other drugs that increase the blood levels of zolpidem. Patients should be warned against driving and other activities requiring complete mental alertness if Stilnox is taken in these circumstances [see *Dosage and Administration (5)* and *Clinical Studies (17.3)*].

Vehicle drivers and machine operators should be warned that, as with other hypnotics, there may be a possible risk of adverse reactions including drowsiness, prolonged reaction time, dizziness, sleepiness, blurred/double vision, reduced alertness, and impaired driving the morning after therapy. In order to minimize this risk a full night of sleep (7-8 hours) is recommended.

Because Stilnox can cause drowsiness and a decreased level of consciousness, patients, particularly the elderly, are at higher risk of falls.

## 8.3 Need to Evaluate for Comorbid Diagnoses

Because sleep disturbances may be the presenting manifestation of a physical and/or psychiatric disorder, symptomatic treatment of insomnia should be initiated only after a careful evaluation of the patient. The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated. Worsening of insomnia or the emergence of new thinking or behavior abnormalities may be the consequence of an unrecognized psychiatric or physical disorder. Such findings have emerged during the course of treatment with sedative/hypnotic drugs, including zolpidem.

## 8.4 Severe Anaphylactic and Anaphylactoid Reactions

Cases of angioedema involving the tongue, glottis or larynx have been reported in patients after taking the first or subsequent doses of sedative-hypnotics, including zolpidem. Some patients have had additional symptoms such as dyspnea, throat closing or nausea and

vomiting that suggest anaphylaxis. Some patients have required medical therapy in the emergency department. If angioedema involves the throat, glottis or larynx, airway obstruction may occur and be fatal. Patients who develop angioedema after treatment with zolpidem should not be rechallenged with the drug.

### **8.5 Abnormal Thinking and Behavioral Changes**

Abnormal thinking and behavior changes have been reported in patients treated with sedative/hypnotics, including Stilnox. Some of these changes included decreased inhibition (e.g. aggressiveness and extroversion that seemed out of character), bizarre behavior, agitation and depersonalization. Visual and auditory hallucinations have been reported.

In controlled trials of Stilnox 10 mg taken at bedtime <1% of adults with insomnia reported hallucinations. In a clinical trial, 7% of pediatric patients treated with Stilnox 0.25 mg/kg taken at bedtime reported hallucinations versus 0% treated with placebo [see *Use in Specific Populations (11)*]. There have been postmarketing reports of delirium with zolpidem use [see *Adverse Reactions (9.2)*].

It can rarely be determined with certainty whether a particular instance of the abnormal behaviors listed above is drug induced, spontaneous in origin, or a result of an underlying psychiatric or physical disorder. Nonetheless, the emergence of any new behavioral sign or symptom of concern requires careful and immediate evaluation.

### **8.6 Use in Patients with Depression**

In primarily depressed patients treated with sedative-hypnotics, worsening of depression, and suicidal thoughts and actions (including completed suicides), have been reported. Suicidal tendencies may be present in such patients and protective measures may be required. Intentional overdosage is more common in this group of patients; therefore, the lowest number of tablets that is feasible should be prescribed for the patient at any one time.

### **8.7 Respiratory Depression**

Although studies with 10 mg zolpidem tartrate did not reveal respiratory depressant effects at hypnotic doses in healthy subjects or in patients with mild to moderate chronic obstructive pulmonary disease (COPD), a reduction in the Total Arousal Index, together with a reduction in lowest oxygen saturation and increase in the times of oxygen desaturation below 80% and 90%, was observed in patients with mild to moderate sleep apnea when treated with zolpidem compared to placebo. Since sedative-hypnotics have the capacity to depress respiratory drive, precautions should be taken if Stilnox is prescribed to patients with compromised respiratory function, or concomitant use with opioids or other CNS depressants. Postmarketing reports of respiratory insufficiency in patients receiving 10 mg of zolpidem tartrate, most of whom had pre-existing respiratory impairment, have been reported. The risk of respiratory depression should be considered prior to prescribing Stilnox in patients with respiratory impairment including sleep apnea and myasthenia gravis or with concomitant opioid use [see *Dosage and Administration (5.3)*, *Drug Interactions (10.1)*].

### **8.8 Precipitation of Hepatic Encephalopathy**

Drugs affecting GABA receptors, such as zolpidem tartrate, have been associated with precipitation of hepatic encephalopathy in patients with hepatic insufficiency. In addition, patients with hepatic insufficiency do not clear the drug as rapidly as normal subjects. Stilnox must not be used in patients with severe hepatic impairment as it may contribute to

encephalopathy [see *Dosage and Administration (5)*, *Use in Specific Populations (11)*, *Clinical Pharmacology (15)*].

### **8.9 Withdrawal Effects**

There have been reports of withdrawal signs and symptoms following the rapid dose decrease or abrupt discontinuation of zolpidem. Monitor patients for tolerance, abuse, and dependence [see *Drug Abuse and Dependence (12.2, 12.3)*].

### **8.9 Severe Injuries**

Zolpidem can cause drowsiness and a decreased level of consciousness, which may lead to falls and consequently to severe injuries. Severe injuries such as hip fractures and intracranial hemorrhage have been reported.

## **9 ADVERSE REACTIONS**

The following serious adverse reactions are discussed in greater detail in other sections of the labeling:

- Complex Sleep Behaviors [see *Warnings and Precautions (8.1)*]
- CNS-Depressant Effects and Next-Day Impairment [see *Warnings and Precautions (8.1)*]
- Severe Anaphylactic and Anaphylactoid Reactions [see *Warnings and Precautions (8.3)*]
- Abnormal Thinking and Behavior Changes [see *Warnings and Precautions (8.4)*]
- Withdrawal Effects [see *Warnings and Precautions (8.8)*]

### **9.1 Clinical Trials Experience**

#### **Associated with Discontinuation of Treatment**

Approximately 4% of 1,701 patients who received zolpidem at all doses (1.25 to 90 mg) in U. S. premarketing clinical trials discontinued treatment because of an adverse reaction.

Reactions most commonly associated with discontinuation from U. S. trials were daytime drowsiness (0.5%), dizziness (0.4%), headache (0.5%), nausea (0.6%), and vomiting (0.5%).

Approximately 4% of 1,959 patients who received zolpidem at all doses (1 to 50 mg) in similar foreign trials discontinued treatment because of an adverse reaction. Reactions most commonly associated with discontinuation from these trials were daytime drowsiness (1.1%), dizziness/vertigo (0.8%), amnesia (0.5%), nausea (0.5%), headache (0.4%), and falls (0.4%).

Data from a clinical study in which selective serotonin reuptake inhibitor (SSRI)-treated patients were given zolpidem revealed that four of the seven discontinuations during double-blind treatment with zolpidem (n= 95) were associated with impaired concentration, continuing or aggravated depression, and manic reaction; one patient treated with placebo (n =97) was discontinued after an attempted suicide.

#### **Most Commonly Observed Adverse Reactions in Controlled Trials**

During short- term treatment (up to 10 nights) with Stilnox at doses up to 10 mg, the most commonly observed adverse reactions associated with the use of zolpidem and seen at statistically significant differences from placebo- treated patients were drowsiness (reported by 2% of zolpidem patients), dizziness (1%), and diarrhea (1%). During longer- term treatment (28 to 35 nights) with zolpidem at doses up to 10 mg, the most commonly observed

adverse reactions associated with the use of zolpidem and seen at statistically significant differences from placebo- treated patients were dizziness (5%) and drugged feelings (3%).

**Adverse Reactions Observed at an Incidence of  $\geq$  1% in Controlled Trials**

The following tables enumerate treatment- emergent adverse reactions frequencies that were observed at an incidence equal to 1% or greater among patients with insomnia who received zolpidem tartrate and at a greater incidence than placebo in U. S. placebo- controlled trials. Events reported by investigators were classified utilizing a modified World Health Organization (WHO) dictionary of preferred terms for the purpose of establishing event frequencies. The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice, in which patient characteristics and other factors differ from those that prevailed in these clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigators involving related drug products and uses, since each group of drug trials is conducted under a different set of conditions. However, the cited figures provide the physician with a basis for estimating the relative contribution of drug and nondrug factors to the incidence of side effects in the population studied.

The following table was derived from results of 11 placebo controlled short term U. S. efficacy trials involving zolpidem in doses ranging from 1. 25 to 20 mg. The table is limited to data from doses up to and including 10 mg, the highest dose recommended for use.

**Table 1: Incidences of Treatment Emergent Adverse Reactions in Placebo-Controlled Clinical Trials Lasting up to 10 Nights (percentage of patients reporting)**

| Body System Adverse Event*                   | Zolpidem<br>( $\leq$ 10 mg)<br>(N=685) | Placebo<br>(N=473) |
|--|--|--------------------|
| <b>Central and Peripheral Nervous System</b> |  |                    |
| Headache                                     | 7                                      | 6                  |
| Drowsiness                                   | 2                                      | -                  |
| Dizziness                                    | 1                                      | -                  |
| <b>Gastrointestinal System</b>               |  |                    |
| Diarrhea                                     | 1                                      | -                  |

\*Reactions reported by at least 1% of patients treated with Stilnox and at a greater frequency than placebo.

The following table was derived from results of three placebo- controlled long- term efficacy trials involving Stilnox (zolpidem tartrate). These trials involved patients with chronic insomnia who were treated for 28 to 35 nights with zolpidem at doses of 5, 10, or 15 mg. The table is limited to data from doses up to and including 10 mg, the highest dose recommended for use. The table includes only adverse events occurring at an incidence of at least 1% for zolpidem patients.

**Table 2: Incidences of Treatment-Emergent Adverse Experiences in Placebo-Controlled Clinical Trials Lasting up to 35 Nights (percentage of patients reporting)**

\*Reactions reported by at least 1% of patients treated with Stilnox and at a greater frequency than placebo.

**Dose Relationship for Adverse Reactions**

There is evidence from dose comparison trials suggesting a dose relationship for many of the adverse reactions associated with zolpidem use, particularly for certain CNS and gastrointestinal adverse events.

| <b>Body System<br/>Adverse Event*</b>        | <b>Zolpidem<br/>(≤10 mg)<br/>(N=152)</b> | <b>Placebo<br/>(N=161)</b> |
|--|--|----------------------------|
| <b>Autonomic Nervous System</b>              |  |                            |
| Dry mouth                                    | 3  | 1                          |
| <b>Body as a Whole</b>                       |  |                            |
| Allergy                                      | 4  | 1                          |
| Back Pain                                    | 3  | 2                          |
| Influenza-like symptoms                      | 2  | -                          |
| Chest pain                                   | 1  | -                          |
| <b>Cardiovascular System</b>                 |  |                            |
| Palpitation                                  | 2  | -                          |
| <b>Central and Peripheral Nervous System</b> |  |                            |
| Drowsiness                                   | 8  | 5                          |
| Dizziness                                    | 5  | 1                          |
| Lethargy                                     | 3  | 1                          |
| Drugged feeling                              | 3  | -                          |
| Lightheadedness                              | 2  | 1                          |
| Depression                                   | 2  | 1                          |
| Abnormal dreams                              | 1  | -                          |
| Amnesia                                      | 1  | -                          |
| Sleep disorder                               | 1  | -                          |
| <b>Gastrointestinal System</b>               |  |                            |
| Diarrhea                                     | 3  | 2                          |
| Abdominal pain                               | 2  | 2                          |
| Constipation                                 | 2  | 1                          |
| <b>Respiratory System</b>                    |  |                            |
| Sinusitis                                    | 4  | 2                          |
| Pharyngitis                                  | 3  | 1                          |
| <b>Skin and Appendages</b>                   |  |                            |
| Rash   | 2  | 1                          |

**Adverse Event Incidence Across the Entire Preapproval Database**

Stilnox was administered to 3,660 subjects in clinical trials throughout the U.S., Canada, and Europe. Treatment-emergent adverse events associated with clinical trial participation were recorded by clinical investigators using terminology of their own choosing. To provide a meaningful estimate of the proportion of individuals experiencing treatment-emergent adverse events, similar types of untoward events were grouped into a smaller number of standardized event categories and classified utilizing a modified World Health Organization (WHO) dictionary of preferred terms.

The frequencies presented, therefore, represent the proportions of the 3,660 individuals exposed to zolpidem, at all doses, who experienced an event of the type cited on at least one occasion while receiving zolpidem. All reported treatment-emergent adverse events are

included, except those already listed in the table above of adverse events in placebo-controlled studies, those coding terms that are so general as to be uninformative, and those events where a drug cause was remote. It is important to emphasize that, although the events reported did occur during treatment with Stilnox, they were not necessarily caused by it.

Adverse events are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: frequent adverse events are defined as those occurring in greater than 1/100 subjects; infrequent adverse events are those occurring in 1/100 to 1/1,000 patients; rare events are those occurring in less than 1/1,000 patients.

**Autonomic nervous system:** Infrequent: increased sweating, pallor, postural hypotension, syncope. Rare: abnormal accommodation, altered saliva, flushing, glaucoma, hypotension, impotence, increased saliva, tenesmus.

**Body as a whole:** Frequent: asthenia. Infrequent: edema, falling, fatigue, fever, malaise, trauma.

Rare: allergic reaction, allergy aggravated, anaphylactic shock, face edema, hot flashes, increased ESR, pain, restless legs, rigors, tolerance increased, weight decrease.

**Cardiovascular system:** Infrequent: cerebrovascular disorder, hypertension, tachycardia. Rare: angina pectoris, arrhythmia, arteritis, circulatory failure, extrasystoles, hypertension aggravated, myocardial infarction, phlebitis, pulmonary embolism, pulmonary edema, varicose veins, ventricular tachycardia.

**Central and peripheral nervous system:** Frequent: ataxia, confusion, euphoria, headache, insomnia, vertigo. Infrequent: agitation, anxiety, decreased cognition, detached, difficulty concentrating, dysarthria, emotional lability, hallucination, hypoesthesia, illusion, leg cramps, migraine, nervousness, paresthesia, sleeping (after daytime dosing), speech disorder, stupor, tremor. Rare: abnormal gait, abnormal thinking, aggressive reaction, apathy, appetite increased, decreased libido, delusion, dementia, depersonalization, dysphasia, feeling strange, hypokinesia, hypotonia, hysteria, intoxicated feeling, manic reaction, neuralgia, neuritis, neuropathy, neurosis, panic attacks, paresis, personality disorder, somnambulism, suicide attempts, tetany, yawning.

**Gastrointestinal system:** Frequent: dyspepsia, hiccup, nausea. Infrequent: anorexia, constipation, dysphagia, flatulence, gastroenteritis, vomiting. Rare: enteritis, eructation, esophagospasm, gastritis, hemorrhoids, intestinal obstruction, rectal hemorrhage, tooth caries.

**Hematologic and lymphatic system:** Rare: anemia, hyperhemoglobinemia, leukopenia, lymphadenopathy, macrocytic anemia, purpura, thrombosis.

**Immunologic system:** Infrequent: infection. Rare: abscess herpes simplex herpes zoster, otitis externa, otitis media.

**Liver and biliary system:** Infrequent: abnormal hepatic function, increased SGPT. Rare: bilirubinemia, increased SGOT.

**Metabolic and nutritional:** Infrequent: hyperglycemia, thirst. Rare: gout, hypercholesteremia, hyperlipidemia, increased alkaline phosphatase, increased BUN, periorbital edema.



**Musculoskeletal system:** Frequent: arthralgia, myalgia. Infrequent: arthritis. Rare: arthrosis, muscle weakness, sciatica, tendinitis.

**Reproductive system:** Infrequent: menstrual disorder, vaginitis. Rare: breast fibroadenosis, breast neoplasm, breast pain.

**Respiratory system:** Frequent: upper respiratory infection, lower respiratory infection. Infrequent: bronchitis, coughing, dyspnea, rhinitis. Rare: bronchospasm, respiratory depression, epistaxis, hypoxia, laryngitis, pneumonia.

**Skin and appendages:** Infrequent: pruritus. Rare: acne, bullous eruption, dermatitis, furunculosis, injection-site inflammation, photosensitivity reaction, urticaria.

**Special senses:** Frequent: diplopia, vision abnormal. Infrequent: eye irritation, eye pain, scleritis, taste perversion, tinnitus. Rare: conjunctivitis, corneal ulceration, lacrimation abnormal, parosmia, photopsia.

**Urogenital system:** Frequent: urinary tract infection. Infrequent: cystitis, urinary incontinence. Rare: acute renal failure, dysuria, micturition frequency, nocturia, polyuria, pyelonephritis, renal pain, urinary retention.

## 9.2 Postmarketing Experience

The following adverse reactions have been identified during postapproval use of Stilnox. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

*Liver and biliary system:* acute hepatocellular, cholestatic or mixed liver injury with or without jaundice (i.e., bilirubin  $>2$  x ULN, alkaline phosphatase  $\geq 2$  x ULN, transaminase  $\geq 5$  x ULN).

*Psychiatric disorders:* delirium

### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form at <https://sideeffects.health.gov.il/>

## 10 DRUG INTERACTIONS

### 10.1 CNS Active Drugs

#### CNS Depressants

Coadministration of zolpidem with other CNS depressants increases the risk of CNS depression. Concomitant use of zolpidem with these drugs may increase drowsiness and psychomotor impairment, including impaired driving ability [see *Warnings and Precautions*

(8.1)]. Zolpidem tartrate was evaluated in healthy volunteers in single-dose interaction studies for several CNS drugs.

#### Alcohol

An additive adverse effect on psychomotor performance between alcohol and oral zolpidem was demonstrated [see *Warnings and Precautions (8.1, 8.2)*].

#### Opioids

The concomitant use of Stilnox with opioids may increase the risk of respiratory depression. Limit dosage and duration of concomitant use of Stilnox and opioids [see *Dosage and Administration (2.3), Warnings and Precautions (5.7)*].

#### Imipramine, Chlorpromazine

Imipramine in combination with zolpidem produced no pharmacokinetic interaction other than a 20% decrease in peak levels of imipramine, but there was an additive effect of decreased alertness. Similarly, chlorpromazine in combination with zolpidem produced no pharmacokinetic interaction, but there was an additive effect of decreased alertness and psychomotor performance [see *Clinical Pharmacology 15.3*].

#### Sertraline

Concomitant administration of zolpidem and sertraline increases exposure to zolpidem [see *Clinical Pharmacology 15.3*].

#### Fluoxetine

After multiple doses of zolpidem tartrate and fluoxetine an increase in the zolpidem half-life (17%) was observed. There was no evidence of an additive effect in psychomotor performance [see *Clinical Pharmacology 15.3*].

#### Haloperidol

A study involving haloperidol and zolpidem revealed no effect of haloperidol on the pharmacokinetics or pharmacodynamics of zolpidem. The lack of a drug interaction following single-dose administration does not predict the absence of an effect following chronic administration [see *Clinical Pharmacology 15.3*].

### **10.2 Drugs that Affect Drug Metabolism via Cytochrome P450**

Some compounds known to induce or inhibit CYP3A may affect exposure to zolpidem. The effect of drugs that induce or inhibit other P450 enzymes on the exposure to zolpidem is not known.

#### CYP3A4 Inducers

##### Rifampin

Rifampin, a CYP3A4 inducer, significantly reduced the exposure to and the pharmacodynamic effects of zolpidem. Use of Rifampin in combination with zolpidem may decrease the efficacy of zolpidem and is not recommended [see *Clinical Pharmacology (15.3)*].

##### St. John's wort

Use of St. John's wort, a CYP3A4 inducer, in combination with zolpidem may decrease blood levels of zolpidem and is not recommended.

### CYP3A4 Inhibitors

#### Ketoconazole

Ketoconazole, a potent CYP3A4 inhibitor, increased the exposure to and pharmacodynamic effects of zolpidem. Consideration should be given to using a lower dose of zolpidem when a potent CYP3A4 inhibitor and zolpidem are given together [see *Clinical Pharmacology (15.3)*].

## **11 USE IN SPECIFIC POPULATIONS**

### **11.1 Pregnancy**

#### Risk Summary

Neonates born to mothers using zolpidem late in the third trimester of pregnancy have been reported to experience symptoms of respiratory depression and sedation [see *Clinical Considerations and Data*]. Published data on the use of zolpidem during pregnancy have not reported a clear association with zolpidem and major birth defects [see *Data*]. Oral administration of zolpidem to pregnant rats and rabbits did not indicate a risk for adverse effects on fetal development at clinically relevant doses [see *Data*].

The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively.

#### Clinical Considerations

##### Fetal/neonatal adverse reactions

Zolpidem crosses the placenta and may produce respiratory depression and sedation in neonates. Monitor neonates exposed to Stilnox during pregnancy and labor for signs of excess sedation, hypotonia, and respiratory depression and manage accordingly.

#### Data

##### Human data

Published data from observational studies, birth registries, and case reports on the use of zolpidem during pregnancy do not report a clear association with zolpidem and major birth defects.

There are limited postmarketing reports of severe to moderate cases of respiratory depression that occurred after birth in neonates whose mothers had taken zolpidem during pregnancy. These cases required artificial ventilation or intratracheal intubation. The majority of neonates recovered within hours to a few weeks after birth once treated.

Zolpidem has been shown to cross the placenta.

## Animal data

Oral administration of zolpidem to pregnant rats during the period of organogenesis at 4, 20, and 100 mg base/kg/day, which are approximately 5, 25, and 120 times the maximum recommended human dose (MRHD) of 10 mg/day (8 mg zolpidem base) based on mg/m<sup>2</sup> body surface area, caused delayed fetal development (incomplete fetal skeletal ossification) at maternally toxic (ataxia) doses 25 and 120 times the MRHD based on mg/m<sup>2</sup> body surface area.

Oral administration of zolpidem to pregnant rabbits during the period of organogenesis at 1, 4, and 16 mg base/kg/day, which are approximately 2.5, 10, and 40 times the MRHD of 10 mg/day (8 mg zolpidem base) based on mg/m<sup>2</sup> body surface area caused embryo-fetal death and delayed fetal development (incomplete fetal skeletal ossification) at a maternally toxic (decreased body weight gain) dose 40 times the MRHD based on mg/m<sup>2</sup> body surface area.

Oral administration of zolpidem to pregnant rats from day 15 of gestation through lactation at 4, 20, and 100 mg base/kg/day, which are approximately 5, 25, and 120 times the MRHD of 10 mg/day (8 mg zolpidem base) based on mg/m<sup>2</sup> body surface area, delayed offspring growth and decreased survival at doses 25 and 120 times, respectively, the MRHD based on mg/m<sup>2</sup> body surface area.

## 11.2 Lactation

### Risk Summary

Limited data from published literature report the presence of zolpidem in human milk. There are reports of excess sedation in infants exposed to zolpidem through breastmilk [*see Clinical Considerations*]. There is no information on the effects of zolpidem on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Stilnox and any potential adverse effects on the breastfed infant from Stilnox or from the underlying maternal condition.

### Clinical Considerations

Infants exposed to Stilnox through breastmilk should be monitored for excess sedation, hypotonia, and respiratory depression. A lactating woman may consider interrupting breastfeeding and pumping and discarding breast milk during treatment and for 23 hours (approximately 5 elimination half-lives) after Stilnox administration in order to minimize drug exposure to a breast fed infant.

## 11.3 Pediatric Use

Stilnox is not recommended for use in children. Safety and effectiveness of zolpidem in pediatric patients below the age of 18 years have not been established.

In an 8-week study, in pediatric patients (aged 6-17 years) with insomnia associated with attention-deficit/hyperactivity disorder (ADHD) an oral solution of zolpidem tartrate dosed at 0.25 mg/kg at bedtime did not decrease sleep latency compared to placebo. Psychiatric and nervous system disorders comprised the most frequent (> 5%) treatment emergent adverse reactions observed with zolpidem versus placebo and included dizziness (23.5% vs. 1.5%), headache (12.5% vs. 9.2%), and hallucinations were reported in 7% of the pediatric patients who received zolpidem; none of the pediatric patients who received placebo reported hallucinations [*see Warnings and Precautions (8.5)*]. Ten patients on zolpidem (7.4%) discontinued treatment due to an adverse reaction.

#### 11.4 Geriatric Use

A total of 154 patients in U. S. controlled clinical trials and 897 patients in non- U. S. clinical trials who received zolpidem were  $\geq 60$  years of age. For a pool of U. S. patients receiving zolpidem at doses of  $\leq 10$  mg or placebo, there were three adverse reactions occurring at an incidence of at least 3% for zolpidem and for which the zolpidem incidence was at least twice the placebo incidence (i.e., they could be considered drug related).

| Adverse Event | Zolpidem | Placebo |
|---------------|----------|---------|
| Dizziness     | 3%       | 0%      |
| Drowsiness    | 5%       | 2%      |
| Diarrhea      | 3%       | 1%      |

A total of 30/ 1,959 (1.5%) non- U. S. patients receiving zolpidem reported falls, including 28/ 30 (93%) who were  $\geq 70$  years of age. Of these 28 patients, 23 (82%) were receiving zolpidem doses  $> 10$  mg. A total of 24/ 1,959 (1.2%) non- U. S. patients receiving zolpidem reported confusion, including 18/ 24 (75%) who were  $\geq 70$  years of age. Of these 18 patients, 14 (78%) were receiving zolpidem doses  $> 10$  mg.

The dose of Stilnox in elderly patients is 5 mg to minimize adverse effects related to impaired motor and/or cognitive performance and unusual sensitivity to sedative/hypnotic drugs[*see Warnings and Precautions (8.1)*].

#### 11.5 Gender Difference in Pharmacokinetics

Women clear zolpidem tartrate from the body at a lower rate than men.  $C_{max}$  and AUC parameters of zolpidem were approximately 45% higher at the same dose in female subjects compared with male subjects. Given the higher blood levels of zolpidem tartrate in women compared to men at a given dose, the recommended initial dose of Stilnox for adult women is 5 mg, and the recommended dose for adult men is 5 or 10 mg.

In geriatric patients, clearance of zolpidem is similar in men and women. The recommended dose of Stilnox in geriatric patients is 5 mg regardless of gender.

#### 11.6 Hepatic Impairment

The recommended dose of Stilnox in patients with hepatic insufficiency is 5 mg once daily immediately before bedtime. Stilnox should not be used in patients with severe hepatic insufficiency [see Dosage and Administration (5.2), Warnings and Precautions (8.8), Clinical Pharmacology (15.3)].

### 12 DRUG ABUSE AND DEPENDENCE

#### 12.1 Controlled Substance

Zolpidem tartrate is classified as a Schedule IV controlled substance by federal regulation.

#### 12.2 Abuse

Abuse and addiction are separate and distinct from physical dependence and tolerance. Abuse is characterized by misuse of the drug for non-medical purposes, often in combination with other psychoactive substances. Tolerance is a state of adaptation in which exposure to a drug induces changes that result in a diminution of one or more of the drug effects over time. Tolerance may occur to both desired and undesired effects of drugs and may develop at different rates for different effects.

Addiction is a primary, chronic, neurobiological disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. Drug addiction is a treatable disease, using a multidisciplinary approach, but relapse is common.

Studies of abuse potential in former drug abusers found that the effects of single doses of zolpidem tartrate 40 mg were similar, but not identical, to diazepam 20 mg, while zolpidem tartrate 10 mg was difficult to distinguish from placebo.

Because persons with a history of addiction to, or abuse of, drugs or alcohol are at increased risk for misuse, abuse and addiction of zolpidem, they should be monitored carefully when receiving zolpidem or any other hypnotic.

### **12.3 Dependence**

Use of Stilnox may lead to the development of physical and/or psychological dependence. The risk of dependence increases with dose and duration of treatment. The risk of abuse and dependence is also greater in patients with a history of alcohol or drug abuse. Stilnox should be used with extreme caution in patients with current or past alcohol or drug abuse.

Physical dependence is a state of adaptation that is manifested by a specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug, and/or administration of an antagonist.

Sedative/hypnotics have produced withdrawal signs and symptoms following abrupt discontinuation. These reported symptoms range from mild dysphoria and insomnia to a withdrawal syndrome that may include abdominal and muscle cramps, vomiting, sweating, tremors, convulsions, and delirium.

The following adverse events, which are considered to meet the DSM-III-R criteria for uncomplicated sedative/hypnotic withdrawal were reported during clinical trials with Stilnox following placebo substitution occurring within 48 hours following last zolpidem treatment: fatigue, nausea, flushing, lightheadedness, uncontrolled crying, emesis, stomach cramps, panic attack, nervousness, and abdominal discomfort. These reported adverse events occurred at an incidence of 1% or less. However, available data cannot provide a reliable estimate of the incidence, if any, of dependence during treatment at recommended doses. There have been postmarketing reports of abuse, dependence and withdrawal with zolpidem.

## **13 OVERDOSAGE**

### **13.1 Signs and Symptoms**

In postmarketing experience of overdose with zolpidem tartrate alone, or in combination with CNS-depressant agents, impairment of consciousness ranging from somnolence to coma, cardiovascular and/or respiratory compromise, and fatal outcomes have been reported.

### **13.2 Recommended Treatment**

General symptomatic and supportive measures should be used along with immediate gastric lavage where appropriate. Intravenous fluids should be administered as needed. Zolpidem's


sedative hypnotic effect was shown to be reduced by flumazenil and therefore may be useful; however, flumazenil administration may contribute to the appearance of neurological symptoms (convulsions). As in all cases of drug overdose, respiration, pulse, blood pressure, and other appropriate signs should be monitored and general supportive measures employed. Hypotension and CNS depression should be monitored and treated by appropriate medical intervention. Sedating drugs should be withheld following zolpidem overdosage, even if excitation occurs. The value of dialysis in the treatment of overdosage has not been determined, although hemodialysis studies in patients with renal failure receiving therapeutic doses have demonstrated that zolpidem is not dialyzable.

As with the management of all overdosage, the possibility of multiple drug ingestion should be considered. The physician may wish to consider contacting a poison control center for up-to-date information on the management of hypnotic drug product overdosage.

#### 14. DESCRIPTION

Stilnox contains zolpidem tartrate, a gamma-aminobutyric acid (GABA) A receptor positive modulator of the imidazopyridine class. Stilnox is available in 10 mg strength tablets for oral administration.

Chemically, zolpidem is N,N,6-trimethyl-2-p-tolylimidazo[1,2-a]pyridine-3-acetamide L-(+)-tartrate (2:1). It has the following structure:



Zolpidem tartrate is a white to off-white crystalline powder that is sparingly soluble in water, alcohol, and propylene glycol. It has a molecular weight of 764.88.

Each Stilnox tablet includes the following inactive ingredients: Lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate (type A), titanium dioxide suspension, magnesium stearate and macrogol 400.

#### 15 CLINICAL PHARMACOLOGY

##### 15.1 Mechanism of Action

Zolpidem is a GABA A receptor positive modulator presumed to exert its therapeutic effects in the short-term treatment of insomnia through binding to the benzodiazepine site of  $\alpha 1$  subunit containing GABA A receptors, increasing the frequency of chloride channel opening resulting in the inhibition of neuronal excitation.

##### 15.2 Pharmacodynamics

Zolpidem binds to GABA A receptors with greater affinity for  $\alpha 1$  subunit relative to  $\alpha 2$  and  $\alpha 3$  subunit containing receptors. Zolpidem has no appreciable binding affinity for  $\alpha 5$  subunit containing GABA A receptors. This binding profile may explain the relative absence of

myorelaxant effects in animal studies. Zolpidem has no appreciable binding affinity for dopaminergic D2, serotonergic 5HT<sub>2</sub>, adrenergic, histaminergic or muscarinic receptors.

### 15.3 Pharmacokinetics

The pharmacokinetic profile of Stilnox is characterized by rapid absorption from the gastrointestinal tract and a short elimination half- life ( $T_{1/2}$ ) in healthy subjects.

In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations ( $C_{max}$ ) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/ mL, respectively, occurring at a mean time ( $T_{max}$ ) of 1.6 hours for both. The mean Stilnox elimination half- life was 2.6 (range: 1.4 to 4.5) and 2.5 (range: 1.4 to 3.8) hours, for the 5 and 10 mg tablets, respectively. Stilnox is converted to inactive metabolites that are eliminated primarily by renal excretion. Stilnox demonstrated linear kinetics in the dose range of 5 to 20 mg. Total protein binding was found to be  $92.5 \pm 0.1\%$  and remained constant, independent of concentration between 40 and 790 ng/ mL. Zolpidem did not accumulate in young adults following nightly dosing with 20 mg zolpidem tartrate tablets for 2 weeks.

A food-effect study in 30 healthy male subjects compared the pharmacokinetics of Stilnox 10 mg when administered while fasting or 20 minutes after a meal. Results demonstrated that with food, mean AUC and  $C_{max}$  were decreased by 15% and 25%, respectively, while mean  $T_{max}$  was prolonged by 60% (from 1.4 to 2.2 hr). The half-life remained unchanged. These results suggest that, for faster sleep onset, Stilnox should not be administered with or immediately after a meal.

#### Special Populations

##### Elderly

In the elderly, the dose for Stilnox should be 5 mg [ *see Warnings and Precautions (8), Dosage and Administration (5)*]. This recommendation is based on several studies in which the mean  $C_{max}$ ,  $T_{1/2}$ , and AUC were significantly increased when compared to results in young adults. In one study of eight elderly subjects (> 70 years), the means for  $C_{max}$ ,  $T_{1/2}$ , and AUC significantly increased by 50% (255 vs 384 ng/ mL), 32% (2.2 vs 2.9 hr), and 64% (955 vs 1,562 ng·hr/mL), respectively, as compared to younger adults (20 to 40 years) following a single 20 mg oral dose. Stilnox did not accumulate in elderly subjects following nightly oral dosing of 10 mg for 1 week.

##### Hepatic Impairment

The pharmacokinetics of Stilnox in eight patients with chronic hepatic insufficiency was compared to results in healthy subjects. Following a single 20 mg oral zolpidem tartrate dose, mean  $C_{max}$  and AUC were found to be two times (250 vs 499 ng/ mL) and five times (788 vs 4,203 ng·hr/ mL) higher, respectively, in hepatically compromised patients.  $T_{max}$  did not change.

The mean half- life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr). Dosing should be modified accordingly in patients with hepatic insufficiency [ *see Dosage and Administration (5.2) Warnings and Precautions (8.8), Use in Specific Populations (11.6)*].

##### Renal Impairment



The pharmacokinetics of zolpidem tartrate was studied in 11 patients with end-stage renal failure (mean  $Cl_{Cr} = 6.5 \pm 1.5$  mL/min) undergoing hemodialysis three times a week, who were dosed with zolpidem tartrate 10 mg orally each day for 14 or 21 days. No statistically significant differences were observed for  $C_{max}$ ,  $T_{max}$ , half-life, and AUC between the first and last day of drug administration when baseline concentration adjustments were made. Zolpidem was not hemodialyzable. No accumulation of unchanged drug appeared after 14 or 21 days. Zolpidem pharmacokinetics was not significantly different in renally impaired patients. No dosage adjustment is necessary in patients with compromised renal function.

## Drug Interactions

### CNS-depressants

Coadministration of zolpidem with other CNS depressants increases the risk of CNS depression [see *Warnings and Precautions (8.2)*]. Zolpidem tartrate was evaluated in healthy volunteers in single-dose interaction studies for several CNS drugs. Imipramine in combination with zolpidem produced no pharmacokinetic interaction other than a 20% decrease in peak levels of imipramine, but there was an additive effect of decreased alertness. Similarly, chlorpromazine in combination with zolpidem produced no pharmacokinetic interaction, but there was an additive effect of decreased alertness and psychomotor performance.

A study involving haloperidol and zolpidem revealed no effect of haloperidol on the pharmacokinetics or pharmacodynamics of zolpidem. The lack of a drug interaction following single-dose administration does not predict the absence of an effect following chronic administration.

An additive adverse effect on psychomotor performance between alcohol and oral zolpidem was demonstrated [see *Warnings and Precautions (8.2)*].

Following five consecutive nightly doses at bedtime of oral zolpidem tartrate 10 mg in the presence of sertraline 50 mg (17 consecutive daily doses, at 7:00 am, in healthy female volunteers), zolpidem  $C_{max}$  was significantly higher (43%) and  $T_{max}$  was significantly decreased (-53%). Pharmacokinetics of sertraline and N-desmethylsertraline were unaffected by zolpidem.

A single-dose interaction study with zolpidem tartrate 10 mg and fluoxetine 20 mg at steady-state levels in male volunteers did not demonstrate any clinically significant pharmacokinetic or pharmacodynamic interactions. When multiple doses of zolpidem and fluoxetine were given at steady state and the concentrations evaluated in healthy females, an increase in the zolpidem half-life (17%) was observed. There was no evidence of an additive effect in psychomotor performance.

### Drugs that affect drug metabolism via cytochrome P450

Some compounds known to inhibit CYP3A may increase exposure to zolpidem. The effect of inhibitors of other P450 enzymes on the pharmacokinetics of zolpidem is unknown.

A single-dose interaction study with zolpidem tartrate 10 mg and itraconazole 200 mg at steady-state levels in male volunteers resulted in a 34% increase in  $AUC_{0-\infty}$  of zolpidem tartrate. There were no pharmacodynamic effects of zolpidem detected on subjective drowsiness, postural sway, or psychomotor performance.

A single-dose interaction study with zolpidem tartrate 10 mg and rifampin 600 mg at steady-state levels in female subjects showed significant reductions of the AUC (-73%),  $C_{max}$  (-58%), and  $T_{1/2}$  (-36%) of zolpidem together with significant reductions in the pharmacodynamic

effects of zolpidem tartrate. Rifampin, a CYP3A4 inducer, significantly reduced the exposure to and the pharmacodynamic effects of zolpidem [see *Drug Interactions (10.2)*].

Similarly, St. John's wort, a CYP3A4 inducer, may also decrease the blood levels of zolpidem.

A single-dose interaction study with zolpidem tartrate 5 mg and ketoconazole, a potent CYP3A4 inhibitor, given as 200 mg twice daily for 2 days increased  $C_{max}$  of zolpidem (30%) and the total AUC of zolpidem (70%) compared to zolpidem alone and prolonged the elimination half-life (30 %) along with an increase in the pharmacodynamic effects of zolpidem [see *Drug Interactions (10.2)*].

Additionally, fluvoxamine (a strong inhibitor of CYP1A2 and a weak inhibitor of CYP3A4 and CYP2C9) and ciprofloxacin (a strong inhibitor of CYP1A2 and a moderate inhibitor of CYP3A4) are also likely to inhibit zolpidem's metabolic pathways, potentially leading to an increase in zolpidem exposure.

Other drugs with no interactions with zolpidem

A study involving cimetidine/zolpidem tartrate and ranitidine/zolpidem tartrate combinations revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of zolpidem.

Zolpidem tartrate had no effect on digoxin pharmacokinetics and did not affect prothrombin time when given with warfarin in healthy subjects.

## 16 NONCLINICAL TOXICOLOGY

### 16.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

#### Carcinogenesis

Zolpidem was administered to mice and rats for 2 years at oral doses of 4, 18, and 80 mg base/kg/day. In mice, these doses are approximately 2.5, 10, and 50 times the MRHD of 10 mg/day (8 mg zolpidem base) based on  $\text{mg}/\text{m}^2$  body surface area and in rats, these doses are approximately 5, 20, and 100 times the MRHD based on  $\text{mg}/\text{m}^2$  body surface area. No evidence of carcinogenic potential was observed in mice. In rats, renal tumors (lipoma, liposarcoma) were seen at the mid and high doses.

#### Mutagenesis

Zolpidem was negative in *in vitro* (bacterial reverse mutation, mouse lymphoma, and chromosomal aberration) and *in vivo* (mouse micronucleus) genetic toxicology assays.

#### Impairment of Fertility

Zolpidem was administered to rats at 4, 20, and 100 mg base/kg/day, which are approximately 5, 25, and 120 times the MRHD of 10 mg/day (8 mg zolpidem base) based on  $\text{mg}/\text{m}^2$  body surface area, prior to and during mating, and continuing in females through postpartum day 25. Zolpidem caused irregular estrus cycles and prolonged precoital intervals at the highest dose tested, which is approximately 120 times the MRHD based on  $\text{mg}/\text{m}^2$  body surface area. The NOAEL for these effects is 25 times the MRHD based on a  $\text{mg}/\text{m}^2$  body surface area. There was no impairment of fertility at any dose tested.

## 17 CLINICAL STUDIES

### 17.1 Transient Insomnia

Normal adults experiencing transient insomnia (n=462) during the first night in a sleep laboratory were evaluated in a double-blind, parallel group, single-night trial comparing two doses of zolpidem (7.5 and 10 mg) and placebo. Both zolpidem doses were superior to placebo on objective (polysomnographic) measures of sleep latency, sleep duration, and number of awakenings.

Normal elderly adults (mean age 68) experiencing transient insomnia (n=35) during the first two nights in a sleep laboratory were evaluated in a double-blind, crossover, 2-night trial comparing four doses of zolpidem (5, 10, 15 and 20 mg) and placebo. All zolpidem doses were superior to placebo on the two primary PSG parameters (sleep latency and efficiency) and all four subjective outcome measures (sleep duration, sleep latency, number of awakenings, and sleep quality).

## **17.2 Chronic Insomnia**

Zolpidem was evaluated in two controlled studies for the treatment of patients with chronic insomnia (most closely resembling primary insomnia, as defined in the APA Diagnostic and Statistical Manual of Mental Disorders, DSM-IV™). Adult outpatients with chronic insomnia (n=75) were evaluated in a double-blind, parallel group, 5-week trial comparing two doses of zolpidem tartrate and placebo. On objective (polysomnographic) measures of sleep latency and sleep efficiency, zolpidem 10 mg was superior to placebo on sleep latency for the first 4 weeks and on sleep efficiency for weeks 2 and 4. Zolpidem was comparable to placebo on number of awakenings at both doses studied.

Adult outpatients (n=141) with chronic insomnia were also evaluated, in a double-blind, parallel group, 4-week trial comparing two doses of zolpidem and placebo. Zolpidem 10 mg was superior to placebo on a subjective measure of sleep latency for all 4 weeks, and on subjective measures of total sleep time, number of awakenings, and sleep quality for the first treatment week.

Increased wakefulness during the last third of the night as measured by polysomnography has not been observed in clinical trials with Stilnox.

## **17.3 Studies Pertinent to Safety Concerns for Sedative/ Hypnotic Drugs**

### Next-Day Residual Effects

Next-day residual effects of Stilnox were evaluated in seven studies involving normal subjects. In three studies in adults (including one study in a phase advance model of transient insomnia) and in one study in elderly subjects, a small but statistically significant decrease in performance was observed in the Digit Symbol Substitution Test (DSST) when compared to placebo. Studies of Stilnox in non-elderly patients with insomnia did not detect evidence of next-day residual effects using the DSST, the Multiple Sleep Latency Test (MSLT), and patient ratings of alertness.

### Rebound Effects

There was no objective (polysomnographic) evidence of rebound insomnia at recommended doses seen in studies evaluating sleep on the nights following discontinuation of Stilnox (zolpidem tartrate). There was subjective evidence of impaired sleep in the elderly on the first post-treatment night at doses above the recommended elderly dose of 5 mg.

### Memory Impairment

Controlled studies in adults utilizing objective measures of memory yielded no consistent evidence of next-day memory impairment following the administration of Stilnox. However, in one study involving zolpidem doses of 10 and 20 mg, there was a significant decrease in next- morning recall of information presented to subjects during peak drug effect (90 minutes post- dose), i. e., these subjects experienced anterograde amnesia. There was also subjective evidence from adverse event data for anterograde amnesia occurring in association with the administration of Stilnox, predominantly at doses above 10 mg.

#### Effects on Sleep Stages

In studies that measured the percentage of sleep time spent in each sleep stage, Stilnox has generally been shown to preserve sleep stages. Sleep time spent in stages 3 and 4 (deep sleep) was found comparable to placebo with only inconsistent, minor changes in REM (paradoxical) sleep at the recommended dose.

### **18 STORAGE AND HANDLING**

Store below 25° C.

The expiry date of the product is indicated on the packaging materials.

### **20 MARKETING AUTHORIZATION HOLDER AND IMPORTER AND ITS ADDRESS**

Sanofi-aventis Israel Ltd. 10 Beni Gaaon St, POB 8090, Netanya

**21REGISTRATION NUMBER** 1045127587

*Revised in August 2022 according to MoH guidelines.*